Search clinical trials for: Dapagliflozin

Total 556 results

Hiddo Lambers Heerspink
AstraZeneca

Unknown

Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria (DIAMOND)

Chronic Kidney Diseases | Proteinuria

Canada, Malaysia, Netherlands
Peking Union Medical College Hospital

Unknown

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
LM Diagnósticos S.L.
AstraZeneca

Unknown

Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes

Type2 Diabetes

Spain
AstraZeneca
Contract Research Organization: USA; PAREXEL Early Phase Clinical Unit Baltimore and other collaborators

Completed

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Asymptomatic Hyperuricemia

United States
Daewoong Pharmaceutical Co. LTD.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers

Healthy

Korea, Republic of
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Type 2 Diabetes Mellitus, CKD and Albuminuria

United States, Spain, Canada, Korea, Republic of, Mexico, Japan, Taiwan, Australia, South Africa
AstraZeneca

Completed

Foxiga Korea Local Phase 4 Study (BEYOND)

Diabetes Mellitus, Type 2

Korea, Republic of
The University of Texas Health Science Center at...
AstraZeneca

Completed

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

Diabetes Mellitus, Type 2

United States
Brigham and Women's Hospital

Unknown

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Diabetes Mellitus, Type 2

United States
AstraZeneca

Completed

Study With Dapagliflozin (GLORIA)

Diabetes Mellitus Type 2

Russian Federation
University of Padova
Azienda Ospedaliera di Padova

Completed

The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients (DAPA-HDL)

Type 2 Diabetes

Italy
AstraZeneca

Completed

Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus (REWARD)

Type II Diabetes Mellitus

United Arab Emirates, Kuwait
University of Dundee
AstraZeneca; NHS Tayside

Completed

Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? (DAPA-LVH)

Type 2 Diabetes | Left Ventricular Hypertrophy

United Kingdom
Woman's
AstraZeneca

Completed

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women (DAPA-GDM)

Diabetes Prevention in Women After GDM Who Are at High-risk

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Unknown

Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.

Obesity | Type 2 Diabetes Mellitus | Cognitive Impairment

China
Lund University

Completed

Vildagliptin Versus Dapagliflozin on Glucagon

Type 2 Diabetes

Sweden
Fundación Pública Andaluza para la Investigación...

Unknown

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Type 2 Diabetes Mellitus

Spain
University of Ioannina

Completed

Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy

Diabetes

Greece
AstraZeneca

Completed

The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
Dong-A ST Co., Ltd.

Completed

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Type2 Diabetes

Korea, Republic of
Christopher Bell
AstraZeneca

Completed

Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

Physical Activity

United States
AstraZeneca

Completed

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

Germany, Slovakia, Czechia, Hungary, Poland
AstraZeneca
Bristol-Myers Squibb

Completed

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 2)

Type 1 Diabetes Mellitus

United States, Germany, Belgium, Canada, Japan, Chile, United Kingdom, Poland, Netherlands, Argentina, Sweden, Russian Federation, Switzerland
AstraZeneca

Completed

Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients (FOREFRONT)

Type 2 Diabetes

India
AstraZeneca

Completed

Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan

Type II Diabetes Mellitus

Taiwan
LG Chem

Completed

Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)

Type 2 Diabetes Mellitus

Korea, Republic of
AstraZeneca

Completed

The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
Hamad Medical Corporation

Unknown

Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF

Risk Reduction

Qatar
Hamad Medical Corporation

Unknown

Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction

Myocardial Infarction | PreDiabetes | CVD | T2DM (Type 2 Diabetes Mellitus)

Qatar
Christopher Bell
AstraZeneca

Terminated

Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

Weight Loss

United States
AstraZeneca

Completed

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Diabetes Mellitus

United States, Hungary, South Africa, Slovakia, Romania, Poland
AstraZeneca

Completed

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Type 2 Diabetes Mellitus

United States, Poland, Mexico, Hungary, Spain, Romania, South Africa, Denmark, Czechia, Sweden
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Type 2 Diabetes Mellitus
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes (DERIVE)

Type 2 Diabetes Mellitus

United States, Italy, Spain, Sweden, Canada, Bulgaria, Poland, Czechia
University of Malaya

Completed

A Real World Experience of Dapagliflozin in Type 2 Diabetes

Type2 Diabetes
Clinical Nutrition Research Centre, Singapore
National University Hospital, Singapore

Completed

Effects of Mixed Spices on Cardiometabolic Function - the PolySPice (PSP) Study (PSP)

Cardiometabolic Risk

Singapore
AstraZeneca

Completed

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

United States, Canada, Czechia, Germany, Russian Federation, Mexico
AstraZeneca
Bristol-Myers Squibb

Completed

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 1)

Type 1 Diabetes Mellitus

United States, Austria, Germany, Italy, Spain, United Kingdom, Belgium, Mexico, Israel, Hungary, Canada, Australia, Denmark, Sweden, Romania, France, Finland
Seoul National University Bundang Hospital

Completed

Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide

Diabetes

Korea, Republic of
Peter Rossing

Completed

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes (DapKid)

Diabetic Nephropathy | Type 2 Diabetes

Denmark
Osaka University

Unknown

Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) (DAPHNIS)

Diabetes Mellitus, Type 2

Japan
Janssen Research & Development, LLC

Completed

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
University of Dundee
European Foundation for the Study of Diabetes

Completed

Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes (REFORM)

Heart Failure | Diabetes

United Kingdom
Chiang Mai University

Completed

Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor

Diabetes Mellitus, Type 2 | Ischemic Heart Disease

Thailand
LG Chem

Unknown

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Type 2 Diabetes Mellitus

Korea, Republic of
Prof. Dr. Thomas Forst

Completed

Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

Type2 Diabetes Mellitus

Germany
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

United States, Hungary, Mexico, South Africa, Romania, Poland
AstraZeneca

Completed

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Healthy Subjects in Fasted and Fed State

Brazil
Slotervaart Hospital
AstraZeneca; Spaarne Gasthuis; Isala

Completed

Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (GluCon-COPD)

Hyperglycemia Steroid-induced

Netherlands
University of Erlangen-Nürnberg Medical School

Completed

Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content (Dapa)

Diabetes Mellitus Type 2

Germany

3

Subscribe